KPC mice with spontaneous pancreatic tumors who received the combination treatment also had an improved median overall survival compared to control‐treated mice, anti‐PD‐1‐alone treated mice, or CD40/chemotherapy‐treated mice.7 Currently, R07009789 (a CD40 agonist mAb) is in phase I clinical trial in conjunction with gemcitabine and nab‐paclitaxel for patients with resectable pancreatic cancer (Table 1). This evidence concerns the gene CD40 and familial pancreatic carcinoma.